GEN-MKT-18-7897-A
Jan 24, 2019 | Blogs, Forensic | 0 comments
Anyone with children will remember that moment in the hospital when the nurse pricks the heel of your tiny new baby to squeeze out a few drops of blood onto a card. It’s an anxious moment but it’s over in a flash, and necessary to screen for rare but serious health conditions. This dried blood spot sampling technique was first introduced 55 years ago, and it has become the method of choice for newborn screening around the world.
But what does this have to do with forensic testing of novel psychoactive substances, after all, it is quite a leap to talk about newborn babies and then onto designer drugs? While dried blood spot sampling and analysis had to overcome hurdles in the early days, particularly due to low analytical throughput, there is a very good reason for its increasing attention in recent years in other applications.
It offers a faster, simpler alternative to serum/plasma or whole blood analysis in drug monitoring for toxicological analysis. In the tech note LC-MS/MS Screening of 64 New Psychoactive Substances Using Dried Blood Spots (as an Alternative to Whole Blood) we demonstrate the advantages, and here’s a rundown:
Sounds good, so what’s the catch? The small sample volume also means that the concentration of the target analyte is potentially quite low (e.g., less than 1 ng/L), requiring a highly sensitive and selective analysis method for detection and quantification. But in theory, there isn’t a catch if there is a solution, mass spectrometry. It is now the most common technique reported in literature for dried blood spot analysis and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) sets the benchmark.
In our method, researchers use the highly sensitive QTRAP® LC-MS/MS in Multiple Reaction Monitoring (MRM) mode using the Scheduled MRM™ Algorithm. The method is applied to authentic samples, and results are compared to a validated whole blood method used for routine analysis of NPS, yielding similar results. LOD was between 1 and 10 ng/ml, no interference from matrix compounds was observed, and the method was proven to be specific and selective for the analytes.
Fill out the form on your right to download the 2018 Forensics Compendium to see this method in its full glory, along with recent advancements developed by the forensics team and a view on where LC-MS/MS technology could take forensics in the future.
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network